XETRA - Delayed Quote EUR

Merck KGaA (MRK.DE)

146.00

-0.75

(-0.51%)

At close: 5:35 PM GMT+2

Merck KGaA's (ETR:MRK) investors will be pleased with their favorable 74% return over the last five years

Stock pickers are generally looking for stocks that will outperform the broader market. And the truth is, you can make...

Simply Wall St. 4 days ago

MKGAF

MKKGY
Merck KGaA (ETR:MRK) Is Paying Out A Dividend Of €2.20

The board of Merck KGaA ( ETR:MRK ) has announced that it will pay a dividend on the 2nd of May, with investors...

Simply Wall St. last month

MRK.DE
-0.51%
Merck KGaA Full Year 2023 Earnings: In Line With Expectations

Merck KGaA ( ETR:MRK ) Full Year 2023 Results Key Financial Results Revenue: €21.0b (down 5.6% from FY 2022). Net...

Simply Wall St. last month

MRK.DE
-0.51%
Analyst Estimates: Here's What Brokers Think Of Merck KGaA (ETR:MRK) After Its Annual Report

Merck KGaA ( ETR:MRK ) last week reported its latest yearly results, which makes it a good time for investors to dive...

Simply Wall St. last month

MRK.DE
-0.51%
Merck KGaA Expects Organic Sales, Earnings Growth This Year

Germany’s Merck expects to gradually return to organic growth this year after reporting a 14% drop in underlying earnings in 2023, which it called a “transitional” year.

The Wall Street Journal last month

MKGAF

MKKGY
MORNING BID EUROPE-ECB also wants more evidence

Federal Reserve Chair Jerome Powell was unambiguous overnight, but the European Central Bank meets today and is more divided and hesitant about committing to monetary easing. The ECB is universally expected to keep its policy rate at a record 4.0%, and policymakers are likely to repeat that they need more evidence inflation is under control and that ongoing wage increases will not give it another leg up. ECB President Christine Lagarde's message will be key, for new economic projections are likely to point to lower economic growth and inflation this year, which may require the central bank to tweak its message slightly.

Reuters last month

AMIGF

AMIGY

DLAKF
Merck Navigates Chip Geopolitics With ‘China For China’ Strategy

(Bloomberg) -- Merck KGaA, a major supplier of specialty materials for semiconductor manufacturing, says it can navigate rising geopolitical tensions between the US and China with what it calls its China for China strategy. Most Read from BloombergJPMorgan Is in a Fight Over Its Client’s Lost $50 Million FortuneGoldman Trader Paid $100 Million Since 2020 Is Stepping DownArgentina’s Milei Devalues Peso by 54% in First Batch of Shock MeasuresNetflix Posts Viewer Data on Every Show, Film for First

Bloomberg 4 months ago

MRK.DE
-0.51%
German Merck’s MS drug falls short in pair of Phase 3 tests

The results dim the outlook of BTK inhibitors as potential autoimmune disease treatments and could have ramifications for Roche, Sanofi and Novartis.

BioPharma Dive 4 months ago

MRK.DE
-0.51%
UPDATE 3-Merck KGaA suffers major blow as MS drug fails in late-stage trials

Merck KGaA's experimental multiple sclerosis (MS) drug missed the primary goal in highly anticipated late-stage trials, dealing a major blow to the German company's growth ambitions and hitting its shares. In two Phase III trials, the compound known as evobrutinib failed to beat Sanofi's established Aubagio in reducing MS relapse rates, Merck said in a statement late on Tuesday. Merck was seen as ahead of Sanofi, Novartis and Roche in a four-way race to develop more targeted MS drugs in a class known as Bruton’s tyrosine kinase (BTK) inhibitors.

Reuters 4 months ago

MRK.DE
-0.51%
SNY

NVS
Merck KGaA's (ETR:MRK) Intrinsic Value Is Potentially 85% Above Its Share Price

Key Insights The projected fair value for Merck KGaA is €297 based on 2 Stage Free Cash Flow to Equity Current share...

Simply Wall St. 4 months ago

MRK.DE
-0.51%
Q3 2023 Exscientia PLC Earnings Call

Q3 2023 Exscientia PLC Earnings Call

Thomson Reuters StreetEvents 5 months ago

EXAI

MRK.DE
-0.51%
SNY
Merck KGaA says FY profit to fall to lower half of target range

FRANKFURT (Reuters) -Germany's diversified group Merck KGaA flagged that full-year operating earnings would likely be in the lower half of its target range on weak demand for specialty materials that are used to make biotech drugs and semiconductors. The maker of pharmaceuticals, lab gear and specialty chemicals confirmed that 2023 earnings before interest, taxes, depreciation and amortisation (EBITDA), adjusted for one-offs, would come in between 5.8 billion euros ($6.21 billion) and 6.4 billion euros but would be "trending in the lower half of the absolute range". Last month, Merck raised the prospect of returning to revenue growth next year, recovering from a slump in demand for its specialty materials to produce biotech drugs and semiconductors.

Reuters 5 months ago

MRK.DE
-0.51%
Merck KGaA's (ETR:MRK) five-year earnings growth trails the notable shareholder returns

When we invest, we're generally looking for stocks that outperform the market average. Buying under-rated businesses is...

Simply Wall St. 5 months ago

MRK.DE
-0.51%
Merck KGaA raises prospect of return to sales growth next year

FRANKFURT (Reuters) -Germany's diversified group Merck KGaA has raised the prospect of returning to revenue growth next year, recovering from a slump in demand for its specialty materials to produce biotech drugs and semiconductors. "We are expecting to leave the transition year 2023 behind, returning to growth in 2024," CEO Belen Garijo told Reuters ahead of the company's capital markets day on Thursday, referring to gains adjusted for currency swings. At the group's key biotech process solutions business, which helps drugmakers run cell cultures and bioreactors, large customers would likely stop drawing on inventories and place orders, "with sales picking up again in the first half of the year", Merck said in a statement.

Reuters 5 months ago

MRK.DE
-0.51%
Merck KGaA says MS drug has blockbuster potential; key data expected in December

The CEO of Germany's Merck KGaA said the company's experimental multiple sclerosis drug can be a "blockbuster", an industry term for annual sales that exceed $1 billion, even after concerns emerged that it may cause liver damage. Merck, seen as leading the race to win approval for a more targeted type of MS drug, said in April that U.S. regulators had paused enrolment of new patients into a trial testing the drug, evobrutinib, knocking the German drugmaker's share price. At the time, the company said the U.S. Food and Drug Administration had cited laboratory results suggesting drug-induced liver injury, but the two affected patients had no symptoms and did not require any medical intervention.

Reuters 5 months ago

MRK.DE
-0.51%
SNY
Merck KGaA's (ETR:MRK) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?

Merck KGaA's (ETR:MRK) stock up by 6.3% over the past three months. Given that the market rewards strong financials in...

Simply Wall St. 6 months ago

MRK.DE
-0.51%
UPDATE 3-Merck KGaA flags steeper profit drop on lower orders from drugmakers

Germany's Merck KGaA on Thursday warned of a steeper earnings decline due to a slump in demand for materials used to produce pharmaceuticals and semiconductors, as its high-tech niche markets get drawn into a wider downturn. In a statement, it cited "persistently high inventory levels of our Life Science customers, the further delayed recovery of the market for semiconductor materials, an increased cost level due to inflation and an even stronger negative foreign exchange impact". The foreign exchange effects would be an additional drag of between 3% and 6%, it added.

Reuters 8 months ago

MRK.DE
-0.51%
Merck KGaA flags steeper profit drop on lower orders from drugmakers

FRANKFURT (Reuters) -Germany's Merck KGaA on Thursday warned of a steeper earnings decline due to a slump in demand for materials used to produce pharmaceuticals and semiconductors, as its high-tech niche markets get drawn into a wider downturn. In a statement, it cited "persistently high inventory levels of our Life Science customers, the further delayed recovery of the market for semiconductor materials, an increased cost level due to inflation and an even stronger negative foreign exchange impact". The foreign exchange effects would be an additional drag of between 3% and 6%, it added.

Reuters 8 months ago

MRK.DE
-0.51%
Data Vault Holdings, Inc. and p-Chip Corporation to Connect Platforms through Enabling IP Licensing Agreement

Data Vault Holdings, Inc., the emerging leader in metaverse data visualization, valuation, and the monetization of data assets, and p-Chip Corporation, a company that is revolutionizing the tracking of physical products and materials with its breakthrough microtransponder technology, today announced they have signed a Letter of Intent (LOI) for an Intellectual Property Licensing Agreement.

PR Newswire 8 months ago

MKGAF

MKKGY
Athinia™ expands partnerships to include Tokyo Electron for real-time collaborative analytics of semiconductor fab equipment performance

Today, Athinia™ announced that its industry-wide many-to-many data ecosystem to accelerate digital transformation and further enable cutting-edge AI is being adopted by more organizations globally. Tokyo Electron Limited (TEL;TYO:8035), a leading capital equipment manufacturer of cutting-edge semiconductor production equipment and technical service will use Athinia™ as a key solution to accelerate its digital and cloud transformation.

PR Newswire 9 months ago

MKGAF

MKKGY

PLTR

Performance Overview

Return	MRK.DE	DAX PERFORMANCE-INDEX
YTD	+1.32%	+5.88%
1-Year	-9.37%	+11.68%
3-Year	+1.41%	+14.73%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Merck KGaA (MRK.DE)

Merck KGaA's (ETR:MRK) investors will be pleased with their favorable 74% return over the last five years

Merck KGaA (ETR:MRK) Is Paying Out A Dividend Of €2.20

Merck KGaA Full Year 2023 Earnings: In Line With Expectations

Analyst Estimates: Here's What Brokers Think Of Merck KGaA (ETR:MRK) After Its Annual Report

Merck KGaA Expects Organic Sales, Earnings Growth This Year

MORNING BID EUROPE-ECB also wants more evidence

Merck Navigates Chip Geopolitics With ‘China For China’ Strategy

German Merck’s MS drug falls short in pair of Phase 3 tests

UPDATE 3-Merck KGaA suffers major blow as MS drug fails in late-stage trials

Merck KGaA's (ETR:MRK) Intrinsic Value Is Potentially 85% Above Its Share Price

Q3 2023 Exscientia PLC Earnings Call

Merck KGaA says FY profit to fall to lower half of target range

Merck KGaA's (ETR:MRK) five-year earnings growth trails the notable shareholder returns

Merck KGaA raises prospect of return to sales growth next year

Merck KGaA says MS drug has blockbuster potential; key data expected in December

Merck KGaA's (ETR:MRK) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?

UPDATE 3-Merck KGaA flags steeper profit drop on lower orders from drugmakers

Merck KGaA flags steeper profit drop on lower orders from drugmakers

Data Vault Holdings, Inc. and p-Chip Corporation to Connect Platforms through Enabling IP Licensing Agreement

Athinia™ expands partnerships to include Tokyo Electron for real-time collaborative analytics of semiconductor fab equipment performance

Performance Overview